Critically, experimental stroke studies have shown that either pharmacologic activation (e.g., salubrinal) or inhibition (e.g., GSK2606414 and ISRIB) of the PERK pathway can improve stroke outcomes. This evidence concerns the gene EIF2AK3 and stroke disorder.